BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Dendreon Corporation 

3005 First Avenue

Seattle  Washington  98121  U.S.A.
Phone: 206-256-4545 Fax: 206-256-0571


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Struggling Dendreon Corporation (DNDN) Plunges After Warning Investors Of Debt Woes 8/13/2014 6:03:14 AM
Flailing Dendreon Corporation (DNDN) Brings In Ex-Johnson & Johnson (JNJ) Exec For Top CEO Post 7/31/2014 6:37:54 AM
Financially Troubled Dendreon Corporation (DNDN) Loses Its CEO 6/9/2014 4:30:01 PM
Dendreon Corporation (DNDN) Release: Treatment With PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer 5/20/2014 10:18:15 AM
Dendreon Corporation (DNDN) Announces Presentation Of PROVENGEĀ® (sipuleucel-T) And DN24-02 Immuno-Oncology Data At The 2014 American Society of Clinical Oncology Annual Meeting 5/15/2014 8:08:39 AM
Dendreon Corporation (DNDN) Announces First Quarter 2014 Results 5/8/2014 9:21:00 AM
Dendreon Corporation (DNDN) To Host Conference Call On May 8 To Announce First Quarter Financial Results 4/29/2014 10:04:28 AM
Dendreon Corporation (DNDN) Release: Immune Responses Enhanced And Sustained When PROVENGE® (Sipuleucel-T) Is Given After Androgen Deprivation Therapy In Biochemically-Recurrent Prostate Cancer 4/11/2014 8:15:28 AM
Dendreon Corporation (DNDN) Announces Plans To Make PROVENGE® Commercially Available In Europe 3/3/2014 8:17:24 AM
Dendreon Corporation (DNDN) Announces Fourth Quarter And 2013 Year End Results 3/3/2014 7:28:27 AM
12345678910...